

Huntington Disease (HD)

**BN40697 - A study to look at tominersen safety over 15 months in people with Huntington's disease**

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

**Trial Status**  
**Completed**

**Trial Runs In**  
**4 Countries**

**Trial Identifier**  
**NCT03342053 ISIS 443139-CS2**  
**BN40697**

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT03342053 ISIS 443139-CS2 BN40697**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
**All**

**Age**  
**>=25 Years**

**Healthy Volunteers**  
**No**